Skip to main content
Equibles
PTCT logo

PTCT · Ptc Therapeutics, Inc. · Metrics

Track PTCT — free

Use PTCT with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research PTCT.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$63.17 +0.25 (+0.39%)
S&P 600 member Russell 2000 member Rebalance outlook locked
Customer concentration — top 4 customers 10% of revenue

4 customers — 10% of revenue (2025)

“During 2025, four of our distributors each accounted for over 10% of our net product sales.”
View the 10-K filed Feb 19, 2026
Market Cap
$5.25B
Shares
83.46M
Volume · Oct 21 17.18K Avg daily vol (3M) 1.12M

PTCT metrics

79 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$62.92
Market cap
$5.25B

Price action

20 metrics
Price change (1W)
+5.0%
Price change (30D)
-3.6%
Price change (3M)
-19.8%
Price change (6M)
-10.9%
Price change (YTD)
-17.2%
Price change (1Y)
-8.0%
Trailing year
Price change (5Y)
+75.4%
52-week high
$89.55
52-week low
$59.24
Change from 52-week high
-29.7%
Change from 52-week low
+6.2%
Annualized volatility
40.6%
Annualized volatility (3M)
38.0%
Beta
0.7
RSI (14D)
47.1
Price vs SMA 50
-6.1%
Price vs SMA 200
-11.7%
Avg volume (3M)
1.12M
Relative volume
0.9
Average dollar volume
$76.28M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
83.46M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
3.5×
reciprocal yield 28.8%
EV / EBITDA
19.3×
reciprocal yield 5.2%
EV / EBIT
27.8×
reciprocal yield 3.6%
P / sales
5.1×
reciprocal yield 19.6%
P / book
—
FCF yield
-0.8%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-0.7%

Historical valuation

8 metrics
P / E historical average (3Y)
7.4×
reciprocal yield 13.5%
P / E historical average (5Y)
7.4×
reciprocal yield 13.5%
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
4.6×
reciprocal yield 21.5%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
2026-10-29
Last earnings
2026-07-30

Profitability

9 metrics
Gross margin
—
Operating margin
12.5%
Trailing 12 months
Net margin
-3.8%
Gross profit (TTM)
$294.85M
Operating profit (TTM)
$125.60M
Net income (TTM)
−$38.38M
Trailing 12 months
Diluted EPS (TTM)
$-0.54
FCF margin
-3.9%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
$5.23
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$-2.52

Growth

11 metrics
Revenue growth YoY
+101.5%
Year over year
Net income growth YoY
—
Revenue (TTM)
$1.01B
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+17.7%
Year over year · more shares
Revenue CAGR (3Y)
+35.3%
Revenue CAGR (5Y)
+35.4%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
-1.2%
Debt / equity
—
Current ratio
3.4
EBITDA (TTM)
$180.90M
Free cash flow (TTM)
−$39.78M
Quick ratio
3.3
Interest coverage
—
Net debt / EBITDA
-9.1
Return on invested capital
—
Trailing 12 months
Net cash
$1.64B
Latest balance sheet
Cash & equivalents
$1.05B
Total assets
$3.25B
Total debt
$590.97M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$30.50M
Capital expenditures (TTM)
$9.28M
R&D (TTM)
$433.31M
SG&A (TTM)
$347.73M
Stock compensation (TTM)
$84.66M
R&D / revenue
43.0%
Stock compensation / revenue
8.4%

Ownership (13F)

9 metrics
13F filers
384
13F filer change QoQ
+29
Institutional ownership
121.6%
Conviction holders (share of 13F filers)
2.1%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
+5.4%
Holder tenure
13.1
Price vs estimated holder cost
+33.6%

Ownership (registered funds)

1 metrics
Index-fund ownership
30.8%

Short interest

3 metrics
Short interest
11.0%
Latest settlement · 6.1 days to cover
Days to cover
6.1d
Short-squeeze score
57 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$8.46M
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1070081 CUSIP 69366J200 13F (30d) 37 filings 36 filers Visit website Investor relations